341 related articles for article (PubMed ID: 26473526)
1. Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatment.
Carbone C; Tamburrino A; Piro G; Boschi F; Cataldo I; Zanotto M; Mina MM; Zanini S; Sbarbati A; Scarpa A; Tortora G; Melisi D
Anticancer Drugs; 2016 Jan; 27(1):29-40. PubMed ID: 26473526
[TBL] [Abstract][Full Text] [Related]
2. Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype.
Carbone C; Moccia T; Zhu C; Paradiso G; Budillon A; Chiao PJ; Abbruzzese JL; Melisi D
Clin Cancer Res; 2011 Sep; 17(17):5822-32. PubMed ID: 21737511
[TBL] [Abstract][Full Text] [Related]
3. CXCR1/2 antagonism with CXCL8/Interleukin-8 analogue CXCL8(3-72)K11R/G31P restricts lung cancer growth by inhibiting tumor cell proliferation and suppressing angiogenesis.
Khan MN; Wang B; Wei J; Zhang Y; Li Q; Luan X; Cheng JW; Gordon JR; Li F; Liu H
Oncotarget; 2015 Aug; 6(25):21315-27. PubMed ID: 26087179
[TBL] [Abstract][Full Text] [Related]
4. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
Lucio-Eterovic AK; Piao Y; de Groot JF
Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589
[TBL] [Abstract][Full Text] [Related]
5. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition.
Piao Y; Liang J; Holmes L; Henry V; Sulman E; de Groot JF
Clin Cancer Res; 2013 Aug; 19(16):4392-403. PubMed ID: 23804423
[TBL] [Abstract][Full Text] [Related]
6. Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients.
Carbone C; Piro G; Simionato F; Ligorio F; Cremolini C; Loupakis F; Alì G; Rossini D; Merz V; Santoro R; Zecchetto C; Zanotto M; Di Nicolantonio F; Bardelli A; Fontanini G; Tortora G; Melisi D
Clin Cancer Res; 2017 Aug; 23(15):4312-4322. PubMed ID: 28298545
[No Abstract] [Full Text] [Related]
7. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
Piao Y; Liang J; Holmes L; Zurita AJ; Henry V; Heymach JV; de Groot JF
Neuro Oncol; 2012 Nov; 14(11):1379-92. PubMed ID: 22965162
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness.
Gaspar NJ; Li L; Kapoun AM; Medicherla S; Reddy M; Li G; O'Young G; Quon D; Henson M; Damm DL; Muiru GT; Murphy A; Higgins LS; Chakravarty S; Wong DH
Mol Pharmacol; 2007 Jul; 72(1):152-61. PubMed ID: 17400764
[TBL] [Abstract][Full Text] [Related]
9. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
[TBL] [Abstract][Full Text] [Related]
10. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
Li JL; Sainson RC; Oon CE; Turley H; Leek R; Sheldon H; Bridges E; Shi W; Snell C; Bowden ET; Wu H; Chowdhury PS; Russell AJ; Montgomery CP; Poulsom R; Harris AL
Cancer Res; 2011 Sep; 71(18):6073-83. PubMed ID: 21803743
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A.
Jia Z; Zhang J; Wei D; Wang L; Yuan P; Le X; Li Q; Yao J; Xie K
Cancer Res; 2007 May; 67(10):4878-85. PubMed ID: 17510417
[TBL] [Abstract][Full Text] [Related]
12. Neuropilin-1 modulates TGFβ signaling to drive glioblastoma growth and recurrence after anti-angiogenic therapy.
Kwiatkowski SC; Guerrero PA; Hirota S; Chen Z; Morales JE; Aghi M; McCarty JH
PLoS One; 2017; 12(9):e0185065. PubMed ID: 28938007
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity.
Horn LA; Riskin J; Hempel HA; Fousek K; Lind H; Hamilton DH; McCampbell KK; Maeda DY; Zebala JA; Su Z; Schlom J; Palena C
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32188703
[TBL] [Abstract][Full Text] [Related]
14. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.
Butler CT; Reynolds AL; Tosetto M; Dillon ET; Guiry PJ; Cagney G; O'Sullivan J; Kennedy BN
J Biol Chem; 2017 Mar; 292(9):3552-3567. PubMed ID: 28035003
[TBL] [Abstract][Full Text] [Related]
15. CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
Devapatla B; Sharma A; Woo S
PLoS One; 2015; 10(9):e0139237. PubMed ID: 26414070
[TBL] [Abstract][Full Text] [Related]
16. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness.
Saidi A; Hagedorn M; Allain N; Verpelli C; Sala C; Bello L; Bikfalvi A; Javerzat S
Int J Cancer; 2009 Sep; 125(5):1054-64. PubMed ID: 19431143
[TBL] [Abstract][Full Text] [Related]
17. The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell carcinoma.
Grépin R; Guyot M; Giuliano S; Boncompagni M; Ambrosetti D; Chamorey E; Scoazec JY; Negrier S; Simonnet H; Pagès G
Cancer Res; 2014 Feb; 74(3):873-83. PubMed ID: 24335961
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
[TBL] [Abstract][Full Text] [Related]
19. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
20. Combined treatment strategies for microtubule stabilizing agent-resistant tumors.
Broggini-Tenzer A; Sharma A; Nytko KJ; Bender S; Vuong V; Orlowski K; Hug D; O'Reilly T; Pruschy M
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25694444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
